Immuno-Oncology | Specialty

Combination Biomarker Is Predictive of Response to Immunotherapy in Metastatic Urothelial Carcinoma

August 13th 2020

The combination of ARID1A mutations and the immune signaling protein CXCL13 proved to be predictive of clinical response and prolonged survival after treatment with checkpoint inhibitors in patients with metastatic urothelial carcinoma.

Dr. Shah on Updated Efficacy of JNJ-4528 in Relapsed/Refractory Myeloma

August 12th 2020

Nina Shah, MD, discusses the updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Navigating Immune-Related Adverse Effects in Oncology

August 12th 2020

Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, discusses the management of immune-related adverse effects in patients who are receiving treatment with checkpoint inhibitors.

Nivolumab Plus Chemotherapy Shows Significant Survival Benefit in Gastric and Esophageal Cancers

August 11th 2020

Nivolumab in combination with chemotherapy as a frontline treatment demonstrated a significant survival benefit in patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma

Dr. Khong on the Potential Benefit of IO/Endocrine Therapy in ER+ Breast Cancer

August 11th 2020

Hung Khong, MD, discusses the potential benefit of combining immunotherapy with endocrine therapy in estrogen receptor–positive, HER2-negative breast cancer.

Nivolumab/Ipilimumab Demonstrates Durable OS Benefit in Malignant Pleural Mesothelioma

August 9th 2020

Nivolumab plus ipilimumab significantly improved overall survival versus chemotherapy in the first-line treatment of patients with unresectable malignant pleural mesothelioma.

Sintilimab/Pemetrexed Regimen Significantly Improves PFS in Advanced NSCLC

August 8th 2020

Sintilimab injection plus pemetrexed and platinum-based therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy alone as a first-line treatment for patients with locally advanced or metastatic nonsquamous non–small cell lung cancer.

Dr. Chiang on the Rationale for Chemoimmunotherapy in Lung Cancer

August 7th 2020

Anne Chiang, MD, PhD, discusses the rationale for combining immunotherapy with chemotherapy in lung cancer.

Dr. Kelly on Window-of-Opportunity Monotherapy Trials in Lung Cancer

August 7th 2020

Karen Kelly, MD, discusses the experimental window-of-opportunity studies with monotherapies in lung cancer.

Experts Analyze Striking ASCO 2020 Data in Small Cell Lung Cancer

August 5th 2020

In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in extensive-stage SCLC and limited-stage SCLC.

Dr. Gandara on the Impact of Immunotherapy on the Tumor Microenvironment in Lung Cancer

August 3rd 2020

David R. Gandara, MD, discusses the impact of immunotherapy on the tumor microenvironment in lung cancer.

Dr. Khong on Endocrine Therapy Combinations in ER+/HER2- Breast Cancer

July 31st 2020

Hung Khong, MD, discusses antiestrogen and immunotherapy combinations in ER-positive, HER2-negative breast cancer.

FDA Approvals Sought for 2 Pembrolizumab Indications in TNBC

July 30th 2020

The FDA has accepted 2 supplemental biologics applications for pembrolizumab in patients with triple-negative breast cancer; these are the first US applications for the anti–PD-1 therapy in breast cancer.

Navigating New Immune-Based Combinations in Advanced NSCLC

July 29th 2020

Joshua K. Sabari, MD, discusses a number of immunotherapy regimens that have emerged in the frontline setting for patients with driver-negative advanced non–small cell lung cancer; however, for many patients, the decision comes down to pembrolizumab monotherapy or pembrolizumab in combination with platinum-doublet chemotherapy.

Dr. Gandara on Measuring TMB in NSCLC

July 28th 2020

David R. Gandara, MD, discusses measuring tumor mutational burden in patients with non–small cell lung cancer who received prior immunotherapy.

Dr. Kelly on Preliminary Data With Neoadjuvant Immunotherapy in Lung Cancer

July 28th 2020

Karen Kelly, MD, discusses encouraging preliminary data with neoadjuvant immunotherapy in lung cancer.

Dr. Braun on Unanswered Questions With PD-1 Blockade in Advanced RCC

July 28th 2020

David A. Braun, MD, PhD, discusses unanswered questions regarding the utility of PD-1 blockade in advanced renal cell carcinoma.

Nivolumab/Ipilimumab Shows Intriguing Clinical Activity in Metastatic Sarcomas

July 28th 2020

Gary K. Schwartz, MD, discusses the clinical findings with the combination of nivolumab and ipilimumab in patients with dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma.

ASCO and ACCC Collaborate to Boost Racial/Ethnic Representation in Cancer Treatment Trials

July 27th 2020

A new collaboration between the American Society of Clinical Oncology and the Association of Community Cancer Centers aims to encourage the enrollment of more racially and ethnically diverse patients with cancer onto clinical trials.

Immunotherapy Use Does Not Correlate With Increased Mortality in Patients with COVID-19, Cancer

July 20th 2020

Treatment with immune checkpoint inhibitors did not increase the risk of mortality in patients with COVID-19 and cancer.